CS
ATHE

Credit Suisse’s Alterity Therapeutics ATHE Stock Holding History

Credit Suisse’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-481
Closed -$65K – 4438
2014
Q2 		$65K Buy
+481
New +$54.8K ﹤0.01% 4578
2014
Q1 		– Sell
-176
Closed -$74K – 4653
2013
Q4 		$74K Sell
176
-307
-64% -$91.9K ﹤0.01% 4502
2013
Q3 		$119K Buy
+483
New +$111K ﹤0.01% 4084

Other funds holding ATHE

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return

Credit Suisse's ATHE Position: Q3 2014 in Review

Credit Suisse sold out of Alterity Therapeutics (ATHE) in Q3 2014, closing a stake of 481 shares — an estimated $65K sold.

Credit Suisse first reported a position in ATHE in Q3 2013 and held it in 3 quarters. The position peaked at $119K in Q3 2013. 26 funds tracked by Wall St. Rank hold ATHE as of Q3 2014.

  • Credit Suisse reported no remaining Alterity Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Credit Suisse sold 481 Alterity Therapeutics shares in Q3 2014, an estimated $65K.
  • Credit Suisse first reported a position in Alterity Therapeutics in Q3 2013 and held it in 3 quarters.
  • Credit Suisse's Alterity Therapeutics position peaked at $119K in Q3 2013.
  • 26 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2014.

Based on Credit Suisse's 13F filing for Q3 2014, filed 14 Nov 2014.